Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 1;111(1):361-367.
doi: 10.3324/haematol.2025.287510. Epub 2025 Jul 31.

Bortezomib-melphalan-prednisone <I>versus</i> lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial

Sara Bringhen  1 , Lorenzo Cani  2 , Nicola Giuliani  3 , Silvia Mangiacavalli  4 , Giulia Benevolo  5 , Elisabetta Antonioli  6 , Renato Zambello  7 , Roberto Ria  8 , Iolanda Donatella Vincelli  9 , Sonia Ronconi  10 , Sonia More  11 , Antonietta Pia Falcone  12 , Alessandro Allegra  13 , Mattia D'Agostino  2 , Andrea Evangelista  14 , Andrea Capra  15 , Elisa Sciorsci  16 , Paola Curci  17 , Patrizia Tosi  18 , Anna Marina Liberati  19 , Anna Maria Cafro  20 , Angelo Belotti  21 , Francesca Patriarca  22 , Donato Mannina  23 , Katia Mancuso  24 , Francesco Cattel  16 , Giovannino Ciccone  14 , Benedetto Bruno  2 , Mario Boccadoro  25 , Alessandra Larocca  2
Affiliations

Bortezomib-melphalan-prednisone <I>versus</i> lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial

Sara Bringhen et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Progression-free survival in the intention-to-treat population. (A) Progression-free survival (PFS). (B) PFS subgroup analysis. CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group Performance Status; HR: Hazard Ratio; IMWG: International Myeloma Working Group; ISS: International Staging System; Rd: lenalidomide-dexamethasone; VMP: bortezomib-melphalan-prednisone.
Figure 2.
Figure 2.
Overall survival in the intention-to-treat population. (A) Overall survival (OS). (B) OS: subgroup analysis. CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group Performance Status; HR: Hazard Ratio; IMWG: International Myeloma Working Group; ISS: International Staging System; Rd: lenalidomide-dexamethasone; VMP: bortezomib-melphalan-prednisone.
See this image and copyright information in PMC

References

    1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. - PubMed
    1. Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301-310. - PMC - PubMed
    1. San-Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31(4):448-455. - PubMed
    1. Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068-2074. - PMC - PubMed
    1. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-917. - PubMed

LinkOut - more resources